Učitavanje...

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice

The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autor: I. V. Kolyadina
Format: Artigo
Jezik:Russo
Izdano: ABV-press 2021-09-01
Serija:Opuholi Ženskoj Reproduktivnoj Sistemy
Teme:
Online pristup:https://ojrs.abvpress.ru/ojrs/article/view/845
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!